Menu Search
Equities

BioArctic AB

B9A:DUS

BioArctic AB

Actions
  • Price (EUR)16.39
  • Today's Change0.50 / 3.15%
  • Shares traded50.00
  • 1 Year change-19.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

  • Revenue in SEK (TTM)167.14m
  • Net income in SEK-232.86m
  • Incorporated2000
  • Employees104.00
  • Location
    BioArctic ABWarfvinges vag 35STOCKHOLM 112 51SwedenSWE
  • Phone+46 86956930
  • Fax+46 86956939
  • Websitehttps://www.bioarctic.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.